63.66

0.16% 0.10

Halozyme Therapeutics Inc (HALO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché HALO Giù? Forum Previsione

Precedente Chiudi:

$63.56

Aprire:

$64.31

Volume 24 ore:

1.13M

Relative Volume:

0.57

Capitalizzazione di mercato:

$7.51B

Reddito:

$947.36M

Utile/perdita netta:

$392.47M

Rapporto P/E:

21.08

EPS:

3.02

Flusso di cassa netto:

$392.71M

1 W Prestazione:

-5.51%

1M Prestazione:

-19.86%

6M Prestazione:

-17.22%

1 anno Prestazione:

+4.26%

Intervallo 1D:

$63.22

$64.58

Intervallo di 1 settimana:

$63.22

$68.40

Portata 52W:

$47.50

$82.22

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Nome

Halozyme Therapeutics Inc

Settore

Healthcare (1116)

Industria

Biotechnology (621)

Telefono

(858) 794-8889

Indirizzo

12390 EL CAMINO REAL, SAN DIEGO, CA

Dipendente

423

Cinguettio

@halozymeinc

Prossima data di guadagno

2025-02-18

Ultimi documenti SEC

HALO's Discussions on Twitter

Compare HALO vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
HALO Halozyme Therapeutics Inc	63.66	7.51B	947.36M	392.47M	392.71M	3.02
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-04	Downgrade	Goldman	Neutral → Sell
2025-10-14	Aggiornamento	Leerink Partners	Underperform → Market Perform
2025-08-06	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2025-07-10	Ripresa	Goldman	Neutral
2025-05-14	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-05-13	Downgrade	Leerink Partners	Market Perform → Underperform
2024-10-07	Downgrade	Wells Fargo	Overweight → Equal Weight
2024-09-19	Downgrade	JP Morgan	Overweight → Neutral
2024-06-07	Downgrade	Piper Sandler	Overweight → Neutral
2024-02-29	Iniziato	TD Cowen	Outperform
2023-07-24	Downgrade	Goldman	Buy → Neutral
2023-07-24	Iniziato	H.C. Wainwright	Buy
2023-05-10	Aggiornamento	Piper Sandler	Neutral → Overweight
2023-03-27	Ripresa	Berenberg	Buy
2023-03-16	Downgrade	SVB Securities	Outperform → Market Perform
2022-12-21	Ripresa	Morgan Stanley	Overweight
2022-11-28	Iniziato	Wells Fargo	Overweight
2022-09-09	Iniziato	Morgan Stanley	Overweight
2022-05-23	Iniziato	SVB Leerink	Outperform
2021-06-14	Iniziato	Evercore ISI	Outperform
2021-05-17	Iniziato	SVB Leerink	Outperform
2021-05-11	Downgrade	Piper Sandler	Overweight → Neutral
2021-01-21	Reiterato	The Benchmark Company	Buy
2020-12-17	Iniziato	Berenberg	Buy
2020-09-14	Ripresa	JP Morgan	Overweight
2020-07-01	Iniziato	The Benchmark Company	Buy
2020-02-05	Aggiornamento	Piper Sandler	Neutral → Overweight
2020-01-09	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2020-01-08	Iniziato	Goldman	Buy
2019-11-05	Aggiornamento	Barclays	Underweight → Equal Weight
2018-10-19	Ripresa	Piper Jaffray	Neutral
2018-05-11	Downgrade	Barclays	Equal Weight → Underweight
2018-01-24	Iniziato	Goldman	Neutral
2017-10-16	Reiterato	Piper Jaffray	Overweight
2017-01-06	Downgrade	Citigroup	Buy → Neutral
2016-11-03	Iniziato	Deutsche Bank	Buy
2015-12-04	Iniziato	Wells Fargo	Outperform
2015-11-18	Iniziato	Citigroup	Buy
2015-09-22	Iniziato	Barclays	Overweight
2015-06-22	Reiterato	JP Morgan	Overweight
2015-03-03	Reiterato	UBS	Buy
2015-02-18	Reiterato	MLV & Co	Buy
2015-01-08	Reiterato	MLV & Co	Buy

Mostra tutto

Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie

Mar 14, 2026

Halozyme names David Ramsay as interim CFO - Investing.com Nigeria

Mar 14, 2026

Halozyme Therapeutics (HALO) Valuation Check After Recent Share Price Pullback - Sahm

Mar 14, 2026

Is Halozyme Therapeutics (HALO) Pricing Look Interesting After Recent Share Price Volatility - simplywall.st

Mar 14, 2026

Halozyme Therapeutics Receives 'Hold' Rating from Analysts - National Today

Mar 14, 2026

Mar 13, 2026

Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness - Yahoo Finance

Mar 13, 2026

Halozyme names David Ramsay as interim CFO By Investing.com - Investing.com India

Mar 13, 2026

Mar 12, 2026

Halozyme Taps David Ramsay as Interim Chief Financial Officer - Contract Pharma

Mar 12, 2026

Halozyme Names David Ramsay Interim Chief Financial Officer - TipRanks

Mar 12, 2026

Halozyme Therapeutics, Inc. Appoints David Ramsay as Interim Chief Financial Officer, Effective March 23, 2026 - marketscreener.com

Mar 12, 2026

Capital Fund Management S.A. Has $15.60 Million Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat

Mar 12, 2026

HALO Stock Price, Quote & Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill

Mar 12, 2026

Mar 11, 2026

Halozyme at Citizens Life Sciences: Strategic Growth and Innovations By Investing.com - Investing.com Nigeria

Mar 11, 2026

Halozyme at Citizens Life Sciences: Strategic Growth and Innovations - Investing.com

Mar 11, 2026

Insider Selling: Cortney Caudill Unloads $1.96M Of Halozyme Therapeutics Stock - Benzinga

Mar 11, 2026